Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy

INTRODUCTION: Tumor necrosis factor (TNF) antagonists reduce the signs and symptoms of spondyloarthritides, including ankylosing spondylitis (AS) and psoriatic arthritis (PsA). Our objective was to evaluate the effectiveness and safety of adalimumab, 40 mg every other week, for patients with AS or P...

Descripción completa

Detalles Bibliográficos
Autores principales: Rudwaleit, Martin, Van den Bosch, Filip, Kron, Martina, Kary, Sonja, Kupper, Hartmut
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2911911/
https://www.ncbi.nlm.nih.gov/pubmed/20553600
http://dx.doi.org/10.1186/ar3054

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2911911/
https://www.ncbi.nlm.nih.gov/pubmed/20553600
http://dx.doi.org/10.1186/ar3054

Ejemplares similares